IPO registrations (S-1, F-1) · Registrants
HYPERION DEFI, INC.
- SEC CIK
- 1682639 · filings on EDGAR ↗
- Name on the registration
- EYENOVIA, INC.
- Former names
- EYENOVIA, INC. (2016–2025)
- Registration
- Form S-1, first filed 2017-12-19, last 2018-12-12; 2 initial registrations, 2 amendments
- Outcome
- Final prospectus filed 2018-01-25; declared effective 2018-01-24
- Industry (SIC)
- Finance Services 6199
- Incorporated in
- DE
- Business address
- 3090 NOWITZKI WAY, SUITE 300, Dallas, TX 75219
- EIN
- 47-1178401
- Ticker
- HYPD (Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- HYPERION DEFI, INC. on the corporate pages
Offering terms
- Proposed price range
- $10.00–$12.00 per share (S-1/A filed 2018-01-11)
- Final price
- $10.00 per share, within the range (424B4 filed 2018-01-25, an initial public offering)
- Shares sold
- 2,730,000
- Gross proceeds
- $27,300,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol EYEN
- Lead underwriters
- Ladenburg Thalmann (1,774,500 shares); Roth Capital Partners (955,500 shares)
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Business registration: HYPERION DEFI, INC. Fuzzy (name and state)
- Form 5500 plan sponsor: HYPERION DEFI, INC. EXACT (EIN (EXACT))
- Form D issuer: HYPERION DEFI, INC. EXACT (CIK (EXACT))
- SEC filer: EYENOVIA, INC. EXACT (CIK (EXACT))
- Person page: Ellen R Strahlman Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director))
- Person page: Stuart M Grant Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (TenPercentOwner))
Filings 10
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2017-12-19 | S-1 | S-1 (registration) | EYENOVIA, INC. | 0001571049-17-008733 ↗ |
| 2018-01-09 | S-1/A | S-1/A (amendment) | EYENOVIA, INC. | 0001144204-18-001370 ↗ |
| 2018-01-11 | S-1/A | S-1/A (amendment) | EYENOVIA, INC. | 0001571049-18-000024 ↗ |
| 2018-01-24 | EFFECT | EFFECT (declared effective) | EYENOVIA, INC. | 9999999995-18-000205 ↗ |
| 2018-01-25 | 424B4 | 424B4 (final prospectus) | EYENOVIA, INC. | 0001144204-18-003703 ↗ |
| 2018-12-12 | S-1 | S-1 (registration) | EYENOVIA, INC. | 0001144204-18-064275 ↗ |
| 2018-12-18 | EFFECT | EFFECT (declared effective) | EYENOVIA, INC. | 9999999995-18-003162 ↗ |
| 2018-12-19 | 424B4 | 424B4 (final prospectus) | EYENOVIA, INC. | 0001144204-18-065389 ↗ |
| 2019-02-12 | EFFECT | EFFECT (declared effective) | EYENOVIA, INC. | 9999999995-19-000199 ↗ |
| 2020-05-13 | EFFECT | EFFECT (declared effective) | EYENOVIA, INC. | 9999999995-20-001144 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2018-01-11 | S-1/A | registration statement | $10.00–$12.00 | 2,730,000 | - | Nasdaq EYEN | 2 | primary document; range, shares headline, cover names 2 | document ↗ | |
| 2018-01-25 | 424B4 | final prospectus | $10.00 | 2,730,000 | $27,300,000 | Nasdaq EYEN | 2 | primary document; price sentence, shares headline, proceeds table, underwriting table 2, cover names 2 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Clasby Jennifer G | Officer | VP, Clinical Operations; VP, Regulatory and Clinical | 9 | 2018–2021 | |
| GANDOLFO JOHN P | Officer | Chief Financial Officer; CHIEF FINANCIAL OFFICER | 12 | 2018–2024 | |
| Ianchulev Tsontcho | Director; Director,Officer; Director,Officer,TenPercentOwner | Chief Executive Officer; CHIEF EXECUTIVE OFFICER | 23 | 2018–2025 | |
| LaBelle Curt H | Director; Director,TenPercentOwner | 8 | 2018–2021 | ||
| MARIO ERNEST | Director | 9 | 2018–2021 | ||
| Senju Pharmaceutical Co., Ltd. | TenPercentOwner | 2 | 2018 | ||
| Yoshida Shuhei | Director,TenPercentOwner | 3 | 2018–2019 | ||
| ESHELMAN FREDRIC N | Director; Director,TenPercentOwner | 6 | 2018–2021 | ||
| LEE KENNETH B JR | Director | 8 | 2018–2022 | ||
| MATHER CHARLES E IV | Director | 18 | 2018–2025 | ||
| SUN ANTHONY Y | Director | 5 | 2018–2021 | ||
| Clauson Luke | Officer | VP, R&D and Manufacturing; VP, Research and Development; VP Research & Development | 5 | 2018–2021 | |
| Rowe Michael M | Director,Officer; Officer | Chief Executive Officer; CHIEF EXECUTIVE OFFICER; Chief Operating Officer; CHIEF OPERATING OFFICER; Vice President, Commercial; Vice President of Marketing | 22 | 2018–2025 | |
| Grant Stuart M. | TenPercentOwner | 27 | 2019–2024 | person page Fuzzy | |
| Haller Julia A | Director | 4 | 2021–2022 | ||
| JACOBSON RACHEL | Director | 11 | 2022–2026 | ||
| Benjamin Stephen Keith | Director | 4 | 2022 | ||
| Palanki Ram | Director | 6 | 2022–2025 | ||
| Strahlman Ellen R | Director | 15 | 2022–2026 | person page Fuzzy | |
| Kern Bren | Officer | Chief Operating Officer; CHIEF OPERATING OFFICER | 5 | 2023–2025 | |
| GELTZEILER MICHAEL S | Director | 9 | 2023–2026 | ||
| Jones Andrew D. | Officer | Chief Financial Officer | 2 | 2024 | |
| Avenue Capital Management II, L.P. | TenPercentOwner | 2 | 2025 | ||
| Avenue Venture Opportunities Fund II, L.P. | TenPercentOwner | 2 | 2025 | ||
| Avenue Venture Opportunities Fund, L.P. | TenPercentOwner | 2 | 2025 | ||
| LASRY MARC | TenPercentOwner | 2 | 2025 | ||
| Jung Hyunsu | Director,Officer | Chief Investment Officer; See Remarks | 7 | 2025–2026 | |
| Walters Happy David | Director | 4 | 2025–2026 | ||
| Knox David R. | Officer | Chief Financial Officer | 5 | 2025–2026 | |
| Rubenstein Robert | Officer | General Counsel | 2 | 2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2025-07-22 | HYPERION DEFI, INC. | Pharmaceuticals | $49,999,999 | $49,999,999 | 5 | 1 |
| 2020-04-07 | EYENOVIA, INC. | Pharmaceuticals | $5,985,000 | $5,985,000 | 82 | 1 |
| 2017-08-14 | EYENOVIA, INC. | Other Health Care | $20,000,000 | $6,000,000 | 10 | 1 |
| 2016-08-24 | EYENOVIA, INC. | Other Health Care | $8,000,000 | $4,041,337 | 4 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Business registration | HYPERION DEFI, INC. | TX | State business registries | name and state |
| Plan sponsor | HYPERION DEFI, INC. | TX | Form 5500 (employee benefit plans) | EIN (EXACT) |
| Form D issuer | HYPERION DEFI, INC. | CA | Form D private offerings | CIK (EXACT) |
| Nonprofit | PROJECT NOVA INC | TX | Nonprofits (IRS Form 990) | same street address and ZIP code, 3090 NOWITZKI WAY STE 300 75219 (FUZZY: a shared address, not proof of a shared organization) |
| SEC filer | HYPERION DEFI, INC. | SEC filers (EDGAR) | CIK (EXACT) | |
| Form 5500 plan sponsor | HYPERION DEFI, INC. | EIN (EXACT) | ||
| Person page | Ellen R Strahlman | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director) | |
| Person page | Stuart M Grant | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (TenPercentOwner) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Finance Services, TX first:
- AVANTAX, INC. TX
- TRIAD FINANCIAL SM LLC TX
- Highland Financial Partners, L.P. TX
- Financial Gravity Companies, Inc. TX
- HeartSciences Inc. TX
- NetSpend Holdings, Inc. TX
- Elevate Credit, Inc. TX
- Cango Inc. TX
- Beneficient TX
- ZeroStack Corp. TX
In other datasets, the same topic (Finance) in TX:
- Lobbying client: 7 ELEVEN, INC. (Federal lobbying (LDA))
Interests: Finance Services · Finance